Author Archives: Bruno Quinney

Researcher in lab
#Clinical trial #CRO

CRO Pharmagene announces re-launch and lab acquisition 

CRO Pharmagene Discovery Services has announced its re-launch, coinciding with its purchase of a human tissue laboratory business.  Pharmagene, originally founded in 1996, has acquired a business near Cambridge, UK. The company says the business is specialised in the performance of laboratory-based research services using consented human tissue across both preclinical and… Read More

#News

Downing Street, London, UK
#BioIndustry Association #Life sciences #UK #UK government

UK government commits £1.5bn to life sciences  

The UK government has pledged £1.5 billion ($2.1 billion) for R&D in life sciences over the next four years.  Speaking at the BioIndustry Association (BIA)’s Gala Dinner, Liz Kendall, the Secretary of State for Science, Innovation and Technology, confirmed the funding for life sciences as part of the government’s… Read More

#News

Immunotherapy
#Cancer immunotherapy #Clinical trial #Melanoma

Immunotherapy before surgery could better treat melanoma 

Administering immunotherapy to melanoma patients before surgery could shrink tumours and improve quality of life.  New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery.   Administering… Read More

#Cancer Research #News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

European Commission
#European Commission #GSK #Respiratory syncytial virus #Vaccines

European Commission approves RSV vaccine 

The European Commission (EC) has approved a respiratory syncytial virus (RSV) vaccine for the treatment of adult patients with lower respiratory tract disease (LRTD) caused by RSV.  Arexy, an adjuvanted recombinant RSV vaccine developed by GSK, will now be available to adult patients in European countries. The treatment was previously approved… Read More

#News #Regulatory

Drug manufacturing
#Gedeon Richter #Neuropsychiatric disorders #Recordati #UK

Gedeon Richter UK announces transfer of neuropsychiatry product 

Pharmaceutical company Gedeon Richter UK has received full marketing and distribution rights for neuropsychiatry treatment Reagila (cariprazine).  Reagila was acquired by Gedeon Richter UK from Recordati Pharmaceuticals, with Gedeon Richter picking up the rights for UK promotion of cariprazine. The drug is currently licensed in the UK for the treatment… Read More

#Business & Investment #News

#Biotech #Immunology #Switzerland

TECregen appoints Dr Klaas Zuideveld as CEO 

Biotechnology company TECregen has appointed Dr Klaas Zuideveld as Chief Executive Officer.  Zuideveld will lead the company’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen immune resilience.  Zuideveld arrives with experience across large pharmaceutical companies and biotech, spanning translational strategy,… Read More

#News

#AI #Organoids #Rare diseases

Partnership set to advance organoid-based disease models  

Cell technology company iXCells Biotechnologies has partnered with Rosebud Biosciences to advance organoid-based models for rare diseases.  The partnership will set out to develop a personalised, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.  iXCells will integrate Rosebud’s organoid generation and characterisation expertise into its existing iPSC solutions, enabling access to… Read More

#Business & Investment #News

Overweight man clutching his knee
#Clinical trial #Obesity

New obesity drug may cause fewer side effects, results show 

A new obesity treatment which could cause fewer side effects has demonstrated a strong pharmacokinetic (PK) profile in preclinical trial.  The treatment, developed by pharmaceutical company Nanexa AB, reportedly indicated a very low ratio between the maximum and minimum plasma concentration over the dosing interval following once-monthly subcutaneous administration.  The company’s… Read More

#News

Cancer cells
#Biomarkers #Breast cancer #Genetic profiling #HER2

Genetic markers drive breast cancer drug resistance, study shows 

Researchers have made a groundbreaking discovery into why some forms of breast cancer are drug resistant.  Cancer scientists at City St George’s, University of London found a ‘molecular signature’ drives drug resistance in an aggressive type of breast cancer known as HER2-positive breast cancer.  The… Read More

#Cancer Research #News

Neuroscience Parkinson's disease
#Neurology #Norway #Parkinson's #Sweden

Parkinson’s could be identified in the blood, study shows 

Early signs of Parkinson’s disease can be identified in the blood, new research suggests.  In a new study published in npj Parkinson’s Disease, a research team from Chalmers University of Technology, Sweden and Oslo University Hospital, Norway identified biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. Read More

#News

#FDA #Investigational New Drug (IND) #Melanoma #Scancell Holdings

FDA clears IND application for melanoma treatment 

The US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a registration Phase III trial of iSCIB1+ Immunobody in advanced melanoma.  The application, submitted by biotechnology company Scancell Holdings, has been cleared with progression free survival as the agreed surrogate endpoint.  Scancell has completed the 140-patient SCOPE Phase II, open-label, multi-centre… Read More

#News #Regulatory

#Allergy #Immune cells #Therapeutic targets

Allergies could be treated by therapeutic target, study finds 

Researchers have uncovered a new target which could help treat severe allergic diseases.  In a study published in The Journal of Allergy and Clinical Immunology, a team led by Associate Professor Tomoaki Ando and Professor Jiro Kitaura at Juntendo University Graduate School of Medicine identified Fab (fragment antigen-binding) antibody… Read More

#News

Lab of the future
#Cancer #The University of Manchester #UK

New UK lab to accelerate cancer diagnostic solutions 

A new state-of-the-art lab has opened in the UK to accelerate the development of cancer diagnostic solutions.  Vortex Biotech has opened a new laboratory at Manchester Science Park, hoping to accelerate the development of cancer diagnostic solutions. The laboratories are designed to GLP-ready specifications, allowing future expansion into clinical trial support and commercial product… Read More

#Cancer Research #News

UK
#Biotech #Europe #UK #UK government

UK is Europe’s leading biotech market, BIA report shows 

The UK retained its position as Europe’s leading national biotech market in 2025, a new report finds.   The BioIndustry Association’s (BIA) report ‘UK biotech financing 2025’ shows the UK market claimed 30% of all European venture financing.  That comes despite a 13.2% year-on-year drop in venture capital investment, totalling £1.79 billion ($2.45 billion) across 58 deals. … Read More

#Business & Investment #News